Instil Bio, Inc. (TIL)Healthcare | Biotechnology | Dallas, United States | NasdaqCM
8.17 USD
-0.23
(-2.682%) ⇩
(April 21, 2026, 12:52 p.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:32 a.m. EDT
Instil Bio presents a lethal combination of fundamental collapse (lead drug discontinued, partnership terminated) and immediate legal overhang (investigation) resulting in a strong short signal. The stock is trading near multi-year lows after a massive 80%+ decline from highs, with no catalyst for recovery in the near term and no dividend support. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.141692 |
| AutoTheta | 0.455208 |
| MSTL | 0.632757 |
| AutoARIMA | 0.662147 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.175 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 70.517 |
| Market Cap | 55,374,840 |
| Forward P/E | -0.56 |
| Beta | 2.03 |
| Website | https://instilbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.49120677 |
| Address1 | 3,963 Maple Avenue |
| Address2 | Suite 350 |
| All Time High | 589.8 |
| All Time Low | 5.67 |
| Ask | 10.66 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 29,740 |
| Average Daily Volume3 Month | 44,844 |
| Average Volume | 44,844 |
| Average Volume10Days | 29,740 |
| Beta | 2.027 |
| Bid | 5.84 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 16.79 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.165 |
| Current Ratio | 39.527 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.328 |
| Day Low | 8.165 |
| Debt To Equity | 70.517 |
| Display Name | Instil Bio |
| Earnings Timestamp End | 1,772,631,000 |
| Earnings Timestamp Start | 1,772,631,000 |
| Ebitda | -52,373,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.187 |
| Enterprise Value | 62,150,780 |
| Eps Forward | -14.64 |
| Eps Trailing Twelve Months | -10.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.4808 |
| Fifty Day Average Change | -0.3157997 |
| Fifty Day Average Change Percent | -0.037237022 |
| Fifty Two Week Change Percent | -49.120678 |
| Fifty Two Week High | 42.79 |
| Fifty Two Week High Change | -34.625 |
| Fifty Two Week High Change Percent | -0.8091844 |
| Fifty Two Week Low | 5.67 |
| Fifty Two Week Low Change | 2.495 |
| Fifty Two Week Low Change Percent | 0.44003525 |
| Fifty Two Week Range | 5.67 - 42.79 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,160,600,000 |
| Float Shares | 3,228,627 |
| Forward Eps | -14.64 |
| Forward P E | -0.5577186 |
| Free Cashflow | -133,371,000 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06294 |
| Held Percent Institutions | 0.65982 |
| Implied Shares Outstanding | 6,781,977 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,701,993,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. |
| Long Name | Instil Bio, Inc. |
| Market | us_market |
| Market Cap | 55,374,840 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_638929728 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -71,372,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 55,815,662 |
| Number Of Analyst Opinions | 2 |
| Open | 8.19 |
| Operating Cashflow | -36,619,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 972 499 3350 |
| Previous Close | 8.39 |
| Price Hint | 2 |
| Price To Book | 0.48630133 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.894 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.22500038 |
| Regular Market Change Percent | -2.6817684 |
| Regular Market Day High | 8.328 |
| Regular Market Day Low | 8.165 |
| Regular Market Day Range | 8.165 - 8.328 |
| Regular Market Open | 8.19 |
| Regular Market Previous Close | 8.39 |
| Regular Market Price | 8.165 |
| Regular Market Time | 1,776,790,348 |
| Regular Market Volume | 4,705 |
| Return On Assets | -0.14159 |
| Return On Equity | -0.50386 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 6,781,976 |
| Shares Percent Shares Out | 0.0612 |
| Shares Short | 414,920 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 416,610 |
| Short Name | Instil Bio, Inc. |
| Short Percent Of Float | 0.1028 |
| Short Ratio | 15.62 |
| Source Interval | 15 |
| State | TX |
| Symbol | TIL |
| Target High Price | 51.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 29.0 |
| Target Median Price | 29.0 |
| Total Cash | 79,668,000 |
| Total Cash Per Share | 11.747 |
| Total Debt | 84,918,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.6494 |
| Two Hundred Day Average Change | -7.4844 |
| Two Hundred Day Average Change Percent | -0.47825477 |
| Type Disp | Equity |
| Volume | 4,705 |
| Website | https://instilbio.com |
| Zip | 75,219 |